NEW YORK, Oct. 15, 2012 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced that the underwriters of its initial public offering exercised in full their option to purchase an additional 750,000 shares of common stock from Intercept. As a result, the total initial public offering size is 5,750,000 shares of common stock to be sold by Intercept. All shares sold in the offering are being sold at a price to the public of $15.00 per share. Closing of the sale of all shares sold in the offering is expected to occur on October 16, 2012.
